MF patients present specific genetic changes too likely anemia-related: patients with Calreticulin (CALR) or MPL thrombopoietin receptor (MPL) gene mutations would appear to have a lower likelihood of developing anemia than triple-negative patients (CALR, MPL, and JAK2 wild types), with underlying unknown mechanisms at this time. This evidence concerns the gene CALR and anemia.